Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of its Executive Management Team will participate in a fireside chat at the Goldman Sachs 40th Annual Healthcare Conference on Wednesday, June 12, 2019 at 9:20 a.m. P.D.T. in Rancho Palos Verdes, California.
A live webcast of the fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. A replay will also be available following the webcast.
Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first, investigational, complex biologic product, AR101, is being developed as a treatment to reduce the frequency and severity and adverse events following exposure to peanut. The BLA for AR101 is under review by the FDA, which granted AR101 Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The Allergenic Products Advisory Committee (APAC) of the FDA will review the BLA for AR101 at a meeting scheduled for September 13, 2019. Aimmune has filed an IND application for its second product, AR201 for the treatment of egg allergy, and intends to start a randomized phase 2 clinical trial in mid-2019. For more information, please see www.aimmune.com.
Source: Aimmune Therapeutics, Inc.